The Effects of e-interventions on the Medical Outcomes of Hemodialysis Patients: A Retrospective Matched Patient Cohort Study

Chang-Chyi Jenq¹,², Cheng-Chieh Hung¹,², Kuo-Chang Juan³ & Kuang-Hung Hsu⁴,⁵,⁶

Aggressively applying e-interventions in the health care industry has become a global trend to improve the quality of medical care. The present retrospective study evaluated the effect of electronic information systems on the quality of medical care provided to hemodialysis (HD) patients. In total, 600 patients (300 patients each in the e-intervention and non-e-intervention groups, were matched for sex, age, HD duration, diabetes, and hypertension) receiving HD at the study institute for four years were included in this study. The e-intervention group had significantly fewer hospitalization days than the non-e-intervention group. Cox regression analysis demonstrated that the non-e-intervention group had a significantly higher mortality rate than the e-intervention group. Stratified analysis revealed significant differences between the e-intervention and non-e-intervention groups in their serum albumin levels, urea reduction ratios, and cardiothoracic ratios at 1-year follow-up. The patients in the e-intervention group had a significantly higher HD blood flow rate, fewer hospitalization days and a lower 4-year all-cause mortality rate than those in the non-e-intervention group. The implementation of the e-intervention improved patient outcomes, but additional studies are required to evaluate the cost effectiveness of such implementations.

A large prospective cohort study by the Taiwan National Institutes of Health in 2008 reported that nearly 2.3 million people in Taiwan (12% of the population) have chronic kidney disease (CKD)¹. When CKD progresses to end-stage renal disease (ESRD), patients require long-term dialysis to sustain life. The medical care system in Taiwan is a single-payer compulsory insurance program. The medical expenditures related to hemodialysis (HD) have increased because of an increase in the number of HD patients over the past few decades². Therefore, monitoring the quality of HD and reducing the complication rate in HD patients have become important concerns that should be addressed to contain medical costs in health care systems.

HD requires vigorous quality control to ensure patient safety and provide high quality care³. Electronic information technology can provide potential benefits in health-care management⁴. Moreover, aggressive application of electronic information technology in the health care industry, referred to as e-interventions, has become a global trend in recent years, and is considered as a necessary tool for providing high quality care⁵. The e-interventions have managed the vast clinical data of HD patients⁶,⁷, thus improving the quality of medical care⁸,⁹.

The present study evaluated the effects of e-interventions on the quality of medical care, particularly on the 4-year all-cause mortality rate, among HD patients in the largest medical system in Taiwan.

¹Department of Nephrology, Chang Gung Memorial Hospital, Linkou, Taiwan. ²College of Medicine, Chang Gung University, Taoyuan City, Taiwan. ³Nephrology Department, Everan Hospital, Taichung, Taiwan. ⁴Laboratory for Epidemiology, Department of Health Care Management, Chang Gung University, Taoyuan City, Taiwan. ⁵Healthy Aging Research Center, Chang Gung University, Taoyuan City, Taiwan. ⁶Department of Urology, Chang Gung Memorial Hospital, Taoyuan City, Taiwan. Correspondence and requests for materials should be addressed to K.-H.H. (email: khsu@mail.cgu.edu.tw)
| Variables                              | All (n = 600) Frequency (%)/Mean ± SD | Non-e group (n = 300) Frequency (%)/Mean ± SD | e group (n = 300) Frequency (%)/Mean ± SD | p value |
|----------------------------------------|--------------------------------------|----------------------------------------------|------------------------------------------|---------|
| **Basic demographics**                 |                                      |                                              |                                          |         |
| Age (years)                            | 58.96 ± 11                           | 59.04 ± 11.15                                | 58.88 ± 10.86                           | 0.8641  |
| Sex                                    |                                      |                                              |                                          |         |
| Male                                   | 312 (52.00)                          | 156 (52.00)                                  | 156 (52.00)                             | 1.0000  |
| Female                                 | 288 (48.00)                          | 144 (48.00)                                  | 144 (48.00)                             |         |
| **Education level**                    |                                      |                                              |                                          |         |
| Under junior high school               | 419 (69.83)                          | 197 (65.67)                                  | 222 (74.00)                             | 0.0328  |
| Senior high school and above           | 181 (30.17)                          | 103 (34.33)                                  | 78 (26.00)                              |         |
| **Occupation**                         |                                      |                                              |                                          |         |
| Laborer                                | 65 (10.83)                           | 34 (11.3)                                    | 31 (10.3)                               | 0.9245  |
| Non-laborer                            | 111 (18.50)                          | 55 (18.3)                                    | 56 (18.7)                               |         |
| Unemployed                              | 424 (70.67)                          | 211 (70.3)                                   | 213 (71.0)                              |         |
| **Marital status**                     |                                      |                                              |                                          |         |
| Married                                | 334 (55.67)                          | 118 (39.33)                                  | 216 (72.00)                             | <0.0001 |
| **Body mass index (kg/m²)**            | 22.56 ± 3.4                          | 22.4 ± 3.55                                  | 22.86 ± 3.1                             | 0.1808  |
| **Medical characteristics and co-morbidities** | |                                                |                                          |         |
| Duration of HD (years)                 | 7.19 ± 5.29                          | 7.16 ± 5.34                                  | 7.22 ± 5.28                             | 0.9019  |
| The cause of end-stage renal disease   |                                      |                                              |                                          |         |
| CGN                                    | 258 (43.00)                          | 149 (49.67)                                  | 109 (36.33)                             | <0.0001 |
| Diabetes mellitus                      | 123 (20.50)                          | 60 (20.00)                                   | 63 (21.00)                              |         |
| Hypertension                           | 155 (25.83)                          | 42 (14.00)                                   | 113 (37.67)                             |         |
| Others                                 | 64 (10.67)                           | 15 (16.33)                                   | 15 (5.00)                               |         |
| **Co-morbidities**                     |                                      |                                              |                                          |         |
| HBV antigen                            | 71 (11.83)                           | 20 (6.67)                                    | 51 (17.00)                              | <0.0001 |
| HCV antibody                           | 96 (16.00)                           | 51 (17.00)                                   | 45 (15.00)                              | 0.5039  |
| Diabetes mellitus                      | 120 (20.00)                          | 60 (20.00)                                   | 60 (20.00)                              | 1.0000  |
| Hypertension                           | 202 (33.67)                          | 101 (33.67)                                  | 101 (33.67)                             | 1.0000  |
| **Vascular access type**               |                                      |                                              |                                          |         |
| A-V fistula                            | 454 (75.67)                          | 225 (75.00)                                  | 229 (76.33)                             | 0.4248  |
| A-V graft                              | 121 (20.17)                          | 65 (21.67)                                   | 56 (18.67)                              |         |
| Double lumen catheter^                 | 25 (4.17)                            | 10 (3.33)                                    | 15 (5.00)                               |         |
| **Physiological and biochemical variables before the e-intervention** | |                                                |                                          |         |
| Anuria                                 | 542 (90.33)                          | 260 (86.67)                                  | 282 (94.00)                             | 0.0021  |
| Surface area of the dialyzer (m²)      | 1.96 ± 0.29                          | 1.98 ± 0.28                                  | 1.94 ± 0.3                              | 0.1484  |
| Blood flow (mL/min)                    | 288.18 ± 40.04                       | 285.67 ± 36.91                               | 290.7 ± 42.86                           | 0.1238  |
| Albumin (g/dL)                         | 3.95 ± 0.34                          | 3.93 ± 0.34                                  | 3.97 ± 0.34                             | 0.1892  |
| Pre-HD creatinine (mg/dL)              | 10.64 ± 2.34                         | 10.54 ± 2.35                                 | 10.74 ± 2.33                            | 0.3254  |
| nPCR (g/kg/day)                        | 1.26 ± 0.38                          | 1.25 ± 0.37                                  | 1.26 ± 0.39                             | 0.9166  |
| tACurea (mg/dL)                        | 41.55 ± 10.92                        | 41.21 ± 10.95                                | 41.86 ± 10.9                            | 0.4758  |
| Potassium (mEq/L)                      | 4.92 ± 0.72                          | 4.97 ± 0.71                                  | 4.88 ± 0.72                             | 0.1469  |
| Kt/V                                   | 1.79 ± 0.32                          | 1.79 ± 0.35                                  | 1.8 ± 0.29                              | 0.6175  |
| URR                                    | 0.77 ± 0.06                          | 0.77 ± 0.06                                  | 0.76 ± 0.07                             | 0.1877  |
| Hematocrit (Hct, %)                    | 31.86 ± 4.09                         | 32.2 ± 4.1                                   | 31.52 ± 4.06                            | 0.0436  |
| Iron administration by vein            | 124 (20.67)                          | 42 (14.00)                                   | 82 (27.33)                              | <0.0001 |
| Monthly EPO usage (1000U/month)^       | 16 (8.22)                            | 16 (8.22)                                    | 18 (11.22)                              | 0.0909  |
| Calcium (mg/dL)                        | 9.67 ± 0.94                          | 9.64 ± 0.93                                  | 9.71 ± 0.95                             | 0.4001  |
| Phosphate (mg/dL)                      | 4.71 ± 1.37                          | 4.63 ± 1.33                                  | 4.79 ± 1.41                             | 0.1679  |
| iPTH (ng/mL)^                          | 134.15                               | 138.3                                        | 127.3                                   | 0.6062  |
|                                      | (49.9, 312.15)                       | (49.9, 324.2)                                | (50, 288.3)                              |         |

Continued
The e-intervention group had a relatively lower 4-year all-cause mortality rate than the non-e-intervention group. Serum albumin levels (3.97 vs. 3.90 g/dL, p = 0.0041), a higher URR (0.78 vs. 0.76, p < 0.0001), a lower cardiothoracic ratio (0.48 vs. 0.50, p < 0.0001), and a faster HD blood flow rate (291 vs. 284 mL/min, p = 0.0032) than the non-e-intervention group (Table 3). Kaplan-Meier survival curve analysis demonstrated that the e-intervention group had significantly fewer hospitalization days than the non-e-intervention group at 1-year post e-intervention (Figure 1). The causes of death during the study period and the mortality rates are shown in Table 1.

### Table 1. Demographic factors and clinical characteristics of the study patients.

| Variables                                      | All (n = 600) Frequency (%) | Non-e group (n = 300) Frequency (%) | e group (n = 300) Frequency (%) | p value |
|------------------------------------------------|-----------------------------|------------------------------------|---------------------------------|---------|
| Total cholesterol (mg/dL)                      | 174.9 ± 37.59               | 172.3 ± 36.94                      | 177.39 ± 38.1                   | 0.1064  |
| Glucose (mg/dL)*                               | 97 (85.132)                 | 99.5 (87.133.5)                    | 95 (82, 129)                    | 0.0277  |
| Cardiothoracic ratio                           | 0.49 ± 0.06                 | 0.5 ± 0.07                         | 0.48 ± 0.06                     | <0.0001 |

### Results

#### Demographic and clinical characteristics of the study groups and the final outcomes.

The mean age of the 600 study patients was 59 years (25–87 years), with a similar male-female distribution (52% vs. 48%). More patients with an education level below junior high school (relatively low education level) were observed in the e-intervention group (74%) than in the non-e-intervention group (65.67%). More patients were married in the e-intervention group (72%) than in the non-e-intervention group (39.33%). Regarding HD vintage, the duration of HD in the e-intervention and non-e-intervention groups was 1–28 years. Chronic glomerulonephritis was the most frequent cause of ESRD in the non-e-intervention group (49.67%), and hypertension was the major cause of ESRD in the e-intervention group (37.67%). More patients had hepatitis B virus infections in the e-intervention group (17%) than in the non-e-intervention group (6.67%). Before the e-intervention, the two study groups differed significantly in their proportion of anuria, haematocrit levels, blood sugar levels, proportion of iron supply, monthly erythropoietin usage, and cardiothoracic ratio. Regarding the outcome variables, the e-intervention group had significantly fewer hospitalization days than the non-e-intervention group at 1-year post e-intervention (Table 1). The causes of death during the study period and the mortality rates are shown in Table 1. The e-intervention group had a relatively lower 4-year all-cause mortality rate than the non-e-intervention group.

#### Statistical analysis results for e-intervention effects.

In multivariable Cox regression analysis, patients in the non-e-intervention group (hazard ratio [HR] = 1.991; 95% confidence interval [CI] = 1.194–3.317) were more likely to die within the 4-year follow-up period than those in the e-intervention group, after adjusting for other variables based on the model selection criteria. In addition, significantly higher mortality rates were observed in patients with a relatively lower education level, unmarried patients, those with lower pre-HD serum creatinine levels, and those with higher sugar levels (Table 2). Stratified analysis revealed significant differences in the serum albumin levels, urea reduction ratio (URR), cardiothoracic ratio and HD blood flow rate of the e-intervention and non-e-intervention groups at 1-year follow-up. The e-intervention group had higher serum albumin levels (3.97 vs. 3.90 g/dL, p = 0.0041), a higher URR (0.78 vs. 0.76, p < 0.0001), a lower cardiothoracic ratio (0.48 vs. 0.50, p < 0.0001), and a faster HD blood flow rate (291 vs. 284 mL/min, p = 0.0032) than the non-e-intervention group (Table 3). Kaplan-Meier survival curve analysis demonstrated that the e-intervention group had a significantly lower 2-year all-cause mortality rate than the non-e-intervention group (Figure 1).

#### Discussion

Currently, the effects and potential benefits of e-intervention application in a healthcare system are a popular area of research. In 1977, Pollak et al. proposed that the objectives of adopting a new record system, such as an online computerized data handling system, to treat patients with renal diseases were: improving the decision-making processes, monitoring the quality of medical care, analyzing the data easily and rapidly, and serving as a useful new teaching model. In the past two decades, many systematic reviews have reported the positive effects of e-interventions. Chaudhry et al. reported that electronic information systems enhance the quality of medical care by increasing the compliance of medical guidelines, strengthening the monitoring of medical practices, and reducing medical errors. Regarding to improving the quality of medical care, the main benefit of these systems is the decreased use of unnecessary medical resources. The main purpose of this study was to assess the effects of e-interventions on the quality of medical care and determine its potential benefits in patient data management in healthcare systems.
| Variables                          | Person-months | Number of death | Univariate measure | Multivariate-adjusted measure |
|-----------------------------------|---------------|-----------------|--------------------|--------------------------------|
| Study groups                      |               |                 |                    |                                |
| Non-e-intervention                | 12880.8       | 65              | 1.264 (0.881, 1.813) | 1.991* (1.194, 3.317)         |
| e-intervention                    | 13442.5       | 54              | —                  | —                              |
| Basic demographics                |               |                 |                    |                                |
| Education level                   |               |                 |                    |                                |
| Under junior high school          | 17977.5       | 104             | 3.267* (1.901, 5.615) | 1.913* (1.012, 3.616)         |
| Senior high school and above      | 8345.8        | 15              | —                  | —                              |
| Occupation                        |               |                 |                    |                                |
| Laborer                           | 3076.0        | 4               | —                  | —                              |
| Non-laborer                       | 5070.4        | 16              | 2.438 (0.815, 7.293) | —                              |
| Unemployment                      | 18177.0       | 99              | 4.274* (1.573, 11.613) | —                              |
| Marital status                    |               |                 |                    |                                |
| Married                           | 13706.1       | 16              | —                  | —                              |
| Not married                       | 12617.2       | 103             | 6.125* (3.616,10.375) | 5.500* (2.934, 10.311)        |
| Body mass index (each increment)  |               |                 | 0.981 (0.926, 1.039) |                                |
| Disease characteristics and co-morbidities |           |                 |                    |                                |
| Duration of HD (years)            |               |                 | 0.973 (0.939, 1.009) |                                |
| Co-morbidities                    |               |                 |                    |                                |
| HBV antigen                       |               |                 |                    |                                |
| Negative                          | 23076.8       | 109             | —                  | —                              |
| Positive                          | 3246.4        | 10              | 0.647 (0.339, 1.237) | 1.246 (0.598, 2.598)          |
| HCV antibody                      |               |                 |                    |                                |
| Negative                          | 22017.7       | 97              | —                  | —                              |
| Positive                          | 4305.5        | 22              | 1.153 (0.728, 1.832) | —                              |
| Diabetes mellitus                 |               |                 |                    |                                |
| No                                | 21570.8       | 70              | —                  | —                              |
| Yes                               | 4752.5        | 49              | 3.271* (2.269, 4.715) | —                              |
| Hypertension                      |               |                 |                    |                                |
| No                                | 17324.5       | 81              | —                  | —                              |
| Yes                               | 8998.8        | 38              | 0.900 (0.612, 1.324) | —                              |
| Vascular access type              |               |                 |                    |                                |
| A-V fistula                       | 20119.3       | 75              | —                  | —                              |
| A-V graft                         | 5252.0        | 31              | 1.596* (1.050, 2.425) | 1.589 (0.953, 2.649)          |
| Double lumen catheter             | 952.0         | 13              | 3.822* (2.119, 6.894) | 1.975 (0.952, 4.095)          |
| Physiological and biochemical variables before the e-intervention |           |                 |                    |                                |
| Daily urine amount (mL/day)       |               |                 | 0.970* (0.949, 0.992) |                                |
| Surface area of the dialyzer (m²) |               |                 | 1.316 (0.695, 2.491) |                                |
| Albumin (g/dL)                    |               |                 | 0.249* (0.150, 0.414) | 0.771 (0.356, 1.669)          |
| Pre-HD creatinine (mg/dL)         |               |                 | 0.748* (0.686, 0.815) | 0.813* (0.708, 0.933)         |
| nPCR (g/kg/day)                   |               |                 | 0.452* (0.257, 0.794) |                                |
| TACurea (mg/dL)                   |               |                 | 0.963* (0.946, 0.981) |                                |
| Potassium (meq/L)                 |               |                 | 0.647* (0.497, 0.843) |                                |
| Kt/V                              |               |                 | 0.881 (0.499, 1.555) |                                |
| URR                               |               |                 | 2.572 (0.153, 43.341) | 4.251 (0.132, 136.648)        |
| Hematocrit (%)                    |               |                 | 0.963 (0.920, 1.008) | 1.034 (0.956, 1.117)          |
| Iron supply                       |               |                 |                    |                                |
| No                                | 20830.5       | 91              | —                  | —                              |
| Yes                               | 5492.8        | 28              | 1.166 (0.763, 1.781) | 1.274 (0.780, 2.081)          |
| Monthly EPO usage (1000U/month)   |               |                 | 1.016 (0.995, 1.037) | 1.010 (0.981, 1.041)          |
| Calcium (mg/dL)                   |               |                 | 0.856 (0.701, 1.047) |                                |
| Phosphate (mg/dL)                 |               |                 | 0.836* (0.727, 0.961) | 1.107 (0.918, 1.334)          |
| iPTH (ng/mL)                      |               |                 | 0.999 (0.999, 1.000) |                                |
| Total cholesterol (mg/dL)         |               |                 | 0.991* (0.985, 0.996) | 0.994 (0.987, 1)              |
| Cardiac thoracic ratio            |               |                 | 555.934* (41.821,7390.177) | 28.888 (0.818, 1020.780)     |
| Continued                         |               |                 |                    |                                |
cardiothoracic ratio, and a higher HD blood flow rate than the non-e-intervention group. Studies have reported that vascular access type associated with the HD blood flow rate influences the mortality in HD patients.

Furthermore, Malaysian study showed that a higher HD blood flow rate (180–210 mL/min) was associated with lower mortality rates in HD patients. However, this finding was not observed in our study. We analyzed the principal diagnoses for patient's hospitalization during the first year of study and observed that infectious diseases (32.3%), cardiovascular or cerebrovascular diseases (21.3%), vascular access-associated disorders (18.3%), gastrointestinal disorders (15.9%), and others (12.2%) were associated with higher mortality rates in HD patients.

Table 2. Factors associated with 4-year all-cause mortality of the hemodialysis patients. HD: hemodialysis; A-V: arteriovenous; EPO: erythropoietin; iPTH: intact parathyroid hormone; URR: urea reduction ratio; HBV: hepatitis B virus; HCV: hepatitis C virus; nPCR: normalized protein catabolic rate; TACurea: time-averaged concentration of urea.

| Variables          | Person-months | Number of death | Univariate measure | Multivariate-adjusted measure |
|--------------------|---------------|-----------------|--------------------|-------------------------------|
|                    |               |                 | HR | 95%CI | HR | 95%CI |
| Glucose (mg/dL)    | —             | —               | 1.004* | (1.003, 1.006) | 1.003* | (1.001, 1.005) |
| Blood flow (cc/min)| —             | —               | 0.989* | (0.984, 0.993) | 1.002 | (0.994, 1.009) |
| Anuria             |               |                 | —              | —                | —              | — |
| Yes                | 23544.8       | 118             | 14.197* (1.984, 101.596) | 6.031 (0.809, 44.966) |
| Hospitalization days | —            | —               | 1.017* (1.007, 1.027) | —              | — |
| Cause of death     |               |                 | 1.017* | (1.006, 1.027) | —              | — |
| GI                 | 11686.3       | 35              | 1.818 (0.944, 3.503) | —              | — |
| CVDs               | 4896.5        | 49              | 6.262* (3.329, 11.779) | —              | — |
| Infections         | 7235.4        | 12              | 5.772* (2.871, 11.602) | —              | — |
| Others             | 2505.1        | 23              | —               | —                | — |

Table 2. Factors associated with 4-year all-cause mortality of the hemodialysis patients. HD: hemodialysis; A-V: arteriovenous; EPO: erythropoietin; iPTH: intact parathyroid hormone; URR: urea reduction ratio; HBV: hepatitis B virus; HCV: hepatitis C virus; nPCR: normalized protein catabolic rate; TACurea: time-averaged concentration of urea.

According to the data obtained before the e-intervention (Table 1) and the outcomes at 1-year post e-intervention (Table 3), the e-intervention group had a relatively higher URR, higher albumin levels, a lower cardiothoracic ratio, and a higher HD blood flow rate than the non-e-intervention group. Studies have reported that vascular access type associated with the HD blood flow rate influences the mortality in HD patients. However, a Japanese study suggested that a low HD blood flow rate may benefit the survival rates in their population. By contrast, the Dialysis Outcomes and Practice Patterns Study in Japan reported that patients with a lower HD blood flow rate (<180 mL/min) had a higher mortality rate than the patients in the reference group with a relatively higher HD blood flow rate (180–210 mL/min). Furthermore, Malaysian study showed that a higher...
those of the other studies in Taiwan25, 26. The distribution of the causes of ESRD was also different compared to the two study groups were matched for sex, age, HD duration, DM, and hypertension and the complicated cases were excluded. Therefore, the mortality rate and hospitalization frequency of the study patients were lower than the effective maintenance of the vascular access. Moreover, adequate HD blood flow rates can lead to adequate HD blood flow rates were negatively associated with 4-year all-cause mortality rates (HR = 0.984~0.993), but did not exhibit significant results in the multivariate-adjusted analysis. Therefore, additional studies are warranted to elucidate the causal relationship between the HD blood flow rate and mortality rates. Third, patients in the two study groups were from different hospital branches, and therefore, closer to their normal ranges in the study patients and did not demonstrate a significant association with the 1-year all-cause mortality.

### Table 3. Clinical characteristics and outcomes associated factors of the study patients one year after the e-intervention

| Variables | All (n = 600) | Non-e group (n = 300) | e group (n = 300) | p-value* |
|-----------|--------------|----------------------|-------------------|----------|
|            | Mean ± SD    | Mean ± SD            | Mean ± SD         |          |
| Hospitalization days (days/person-years) | 1.66 ± 0.98 | 3.39 ± 12.77 | 0.00 ± 0.00 | <0.0001 |
| Blood flow (cc/min) | 287.39 ± 39.31 | 283.52 ± 35.97 | 291.08 ± 41.99 | 0.0032 |
| 1-year all-cause mortality | | | | |
| Deaths | 13 (2.17) | 13 (4.33) | 0 (0.0) | <0.0001 |
| Survivors | 909 (97.5) | 287 (95.67) | 300 (100.0) | |
| Physiological and biochemical variables | | | | |
| Albumin (g/dL) | 3.94 ± 0.33 | 3.9 ± 0.34 | 3.97 ± 0.32 | 0.0041 |
| Pre-HD creatinine (mg/dL) | 10.76 ± 2.48 | 10.73 ± 2.54 | 10.78 ± 2.44 | 0.733 |
| nPCR (g/kg/day) | 1.28 ± 0.43 | 1.28 ± 0.43 | 1.28 ± 0.44 | 0.8284 |
| TACurea (mg/dL) | 41.87 ± 11.54 | 42.2 ± 12.3 | 41.55 ± 10.79 | 0.569 |
| Potassium (meq/L) | 4.93 ± 0.76 | 4.93 ± 0.77 | 4.94 ± 0.75 | 0.7899 |
| Kt/V | 1.51 ± 0.35 | 1.51 ± 0.42 | 1.5 ± 0.26 | 0.9566 |
| URR | 0.77 ± 0.06 | 0.76 ± 0.06 | 0.78 ± 0.06 | <0.0001 |
| Hematocrit (%) | 31.88 ± 4.1 | 32.05 ± 4.26 | 31.72 ± 3.94 | 0.6287 |
| Iron administration by vein | | | | |
| No | 463 (78.88) | 236 (82.23) | 227 (75.67) | 0.0509 |
| Yes | 124 (21.12) | 51 (17.77) | 73 (24.33) | |
| Monthly EPO usage (100U/month)* | 16 (10.22) | 16 (8.20) | 16 (12.22) | 0.0979 |
| Calcium (mg/dL) | 9.76 ± 0.99 | 9.82 ± 1.01 | 9.71 ± 0.96 | 0.2305 |
| Phosphate (mg/dL) | 4.9 ± 1.49 | 4.89 ± 1.57 | 4.91 ± 1.42 | 0.8149 |
| iPTH (ng/mL)* | 181.5 (62.1, 455.2) | 178.2 (53.4, 441.5) | 188.1 (71.7, 478.25) | 0.6106 |
| Total cholesterol (mg/dL) | 169.69 ± 36.21 | 168.94 ± 35.75 | 170.37 ± 36.66 | 0.6157 |
| Glucose (mg/dL)* | 96.0 (84.0, 128.0) | 97 (85, 129) | 94 (82, 127) | 0.2219 |
| Cardiothoracic ratio | 0.49 ± 0.06 | 0.50 ± 0.07 | 0.48 ± 0.06 | <0.0001 |

HD blood flow rate is associated with a higher quality of life24. A high HD blood flow rate may be attributed to the effective maintenance of the vascular access. Moreover, adequate HD blood flow rates can lead to adequate clearance, which is demonstrated by an increased Kt/V and URR25. We performed Cox regression analysis for the 4-year all-cause mortality rates based on the biophysiological indicators measured 1-year post e-intervention. The HD blood flow rates were negatively associated with 4-year all-cause mortality rates (HR = 0.989, 95% CI = 0.984~0.993), but did not exhibit significant results in the multivariate-adjusted analysis. Therefore, additional studies are warranted to elucidate the causal relationship between the HD blood flow rate and mortality rate.

The present study has numerous limitations. First, this study has a retrospective design, and cases with missing medical data and records were excluded. Therefore, the number of cases was reduced, which might have affected the integrity of the study results. Second, we intended to analyze the effects of e-interventions, therefore, the two study groups were matched for sex, age, HD duration, DM, and hypertension and the complicated cases were excluded. Therefore, the mortality rate and hospitalization frequency of the study patients were lower than those of the other studies in Taiwan25, 26. The distribution of the causes of ESRD was also different compared to other studies in Taiwan25. Therefore, the predictors, such as serum phosphate and albumin levels, were closer to their normal ranges in the study patients and did not demonstrate a significant association with the mortality rates. Third, patients in the two study groups were from different hospital branches, and therefore some innate differences may have existed. Although the data were adjusted in the statistical analysis, interference effects cannot be completely ruled out. Fourth, the current health care system in Taiwan is a single-payer compulsory social insurance plan. Some prospective payment system policy interventions, including global budget, and pay-for-performance, were introduced during 2004–2005. Therefore, the data prior to 2005 were not included to avoid such historic effects on the results. Finally, because of the constant changes in the health care environment and health policies, the present results can only reflect the effects of the e-intervention during the specific study period and of the unique electronic information systems of the research institutes involved in the present study.
Conclusion

Due to the rapid advances in medical technology and increasing attention on health and medical effectiveness, the objective of HD treatment has gradually changed from the passive replacement kidney functions to the active reduction of complications and improvement in discomfort during HD. HD is expected to not only prolong life but also improve the quality of life. The e-intervention adopted for HD care in the present study showed promising results. The e-intervention group had a significantly higher HD blood flow rate, fewer hospitalization days, and a relatively lower 4-year all-cause mortality rate than the non-e-intervention group.
The implementation of e-interventions is a current trend in medical management to simplify medical-related processes and save medical resources. The use of an e-intervention to analyze and monitor medical processes can also help to provide safer medical services. However, e-interventions require substantial investments in hardware and software. In addition, medical personnel require education and training to appropriately operate these systems. Although e-interventions improved patient outcomes in the present study, additional studies are required to evaluate the cost effectiveness of such e-interventions.

Methods

Study patients and interventions. This retrospective was conducted using the clinical data abstracted from the Chang Gung Memorial Hospital (CGMH) information system. We evaluated the effectiveness of a quality improvement intervention by introducing an integrated information system for HD patient care. Although the analysis was performed using a prospective method, the nature and protocol of this study were reviewed and approved by the Institutional Review Board (IRB) of CGMH. The IRB provided an exemption certificate for this review (99–2617B). Therefore, written or verbal informed consent was not required from the study patients. All research methods in this study were performed in accordance with the approved guidelines.

The patients who received regular HD at any of the three CGMHs (Taoyuan, Taipei, and Linkou) in March 2007 were included in this study. Of the 1,208 HD patients, 276 were excluded due to one of the following reasons: (1) receiving regular HD for < 1 year; (2) history of hospitalization within 1 year before March 2007; (3) receiving HD less than three times a week between March 2006 and February 2011; (4) receiving any alterations of the vascular access between March 2006 and February 2011; and (5) receiving HD at a different institution between March 2006 and February 2011. The remaining 932 HD patients were divided into the e-intervention group (patients who received HD at Taoyuan CGMH and were started on e-intervention from March 2007) and the non-e-intervention group (patients who received HD at Linkou CGMH and Taipei CGMH and did not receive e-intervention from March 2007) according to each patient’s medical care settings. After matching for sex, age ± 3 years, HD duration, DM and hypertension, a total of 600 HD patients (300 patients each in the e-intervention and non-e-intervention groups) were recruited. Figure 2 shows the consort diagram of the study patients.

The e-intervention involved the use of the HD electronic information management system of CGMH. It applied electronic information technology and integrated information from the HD patient information system, physician order entry system, and nursing system. It had access to the existing patient medical data system which provided medical records of all patients in CGMH. The e-intervention created a platform to share information with practitioners and patients and provide assisted patient-centered medical care. When a HD patient was admitted to the HD room, a code reader would record patient’s identity and bed number and link with results from an electronic body weighing machine. The pre-dialysis preparation, including dialyzer, dialysate, and heparinization preparations, was performed by a technician according to the data present in the electronic information system. After starting the HD process, the ultrafiltration volume setting was established on the basis of the dry weight and measured body weight data in the electronic information system. During HD, patient data including blood pressure, body temperature, blood flow rate, dialysate flow rate and vascular access pressure, were recorded automatically and uploaded into the electronic information system. The HD nurses were informed by an e-alert system if any abnormality was detected. The system also provided physicians’ orders to the HD nurses, who could promptly perform medical practices accordingly. Nearly twenty software interfaces in the electronic...
information system, including medical records, physicians' orders, medication data, medical devices, medical materials, HD schedules, HD indicators, data statistics, pricing, administrative affairs, and staff's duty scheduling, facilitated healthcare management. The major objectives of the e-intervention were to: (1) improve the efficiency of the medical care protocol by shortening the prescription time, prompting laboratory reports, and accelerating the acquisition of imaging information (electronic retrieval system for X ray images); (2) reduce the workload of medical personnel, including saving time on laboratory data retrieval, prompt prescription of medications on-line, and providing an expert assistance platform to assess the comprehensiveness of the patient data; (3) enhance the accuracy of medical processes including scheduling, prescriptions, laboratory reports, and medical records; and (4) increase patient safety and medical care quality through information integration. The patients in the e-intervention group were managed by the HD electronic information management system and the conventional patient medical data system. The patients in the non-e-intervention group were managed by their physicians and nurses using traditional paper-driven systems and conventional patient medical data systems. Figure 3 presents a detailed description of the e-intervention and non-e-intervention group.

Data collection. The basic demographic variables and clinical data, including age, sex, education levels, occupation, marital status, HD duration, causes of ESRD (including chronic glomerulonephritis, DM, hypertension, and other chronic conditions), and history of diseases and health conditions (including hepatitis B virus, hepatitis C virus (HCV), vascular access types, DM, hypertension, and body mass index), of HD patients were assessed in March 2007 using a questionnaire and confirmed with a medical chart review. In addition, physiological and biochemical variables (including the daily amount of urine, dialyzer surface area, albumin, pre-HD creatinine, normalized protein catabolic rate, time-averaged concentration of blood urea nitrogen, potassium levels, Kt/V, URR, haematocrit levels, monthly erythropoietin usage, calcium, phosphate levels, intact parathyroid hormone, total cholesterol, cardiothoracic ratio, and iron supply) before the e-intervention (in February 2007) and at 1-year post e-intervention (in March 2008) were obtained. Intravenous of iron administration was prescribed to patients according to the protocol of the CGMH HD room: hematocrit < 28%, transferrin saturation < 20% and ferritin level < 200 μg/mL, patients were intravenously administered with 1 g of Sucrofer® (iron sucrose complex 2%, 20 mg Fe per mL, 5 mL per amp), divided to 10 times and was given one time a week for 10 weeks. During the 4-year follow-up period until February 2011, outcome variables, including total length of hospitalization and 4-year all-cause mortality rate were measured. Figure 4 presents a detailed description of the time study schedule.

Statistical analysis. Numerical and categorical variables are presented as means ± standard deviations, and frequencies and percentages, respectively. The independent sample t test was used to compare the means of continuous variables and normally distributed data; otherwise, the Mann Whitney U test was used. The chi-squared test was used to compare the differences between categorical variables. A Cox regression model was used to determine the strength of the associations between the study groups and 4-year all-cause mortality, after examining (and adjusting for) the effects from other selected variables. A p value of < 0.1 was pre-determined as the multivariable model selection criteria among variables with p < 0.05 in the univariate analysis after considering the effects of co-linearity among candidate variables. The results are expressed as multivariate-adjusted HR and corresponding 95% CIs. In stratified analysis, the causes of ESRD and the vascular access types were further categorized separately.
into groups and visualized using bar charts. Cumulative survival curves as a function of time were constructed using the Kaplan Meier approach, and the log rank test was conducted to determine their statistical significance. SAS software version 9.30 (Cary, NC, USA) was used for all statistical analyses in this study.

References
1. Wen, C. P. et al. All-cause mortality attributable to chronic kidney disease (CKD): a prospective cohort study based on 462,293 adults in Taiwan. Lancet. 371, 2173–2182 (2008).
2. National Kidney Foundation. K/DOQI Clinical Practice Guidelines for Hemodialysis Adequacy. Am J Kidney Dis. 37, S7–S64 (2001).
3. De Palma, J. R. Adequate hemodialysis schedule. N Engl J Med. 285, 353–354 (1971).
4. Pollak, V. E. Computerized medical information system enhances quality assurance. A 10-year experience in chronic maintenance hemodialysis patients. Nephron. 54, 109–116 (1990).
5. Dean, B. B. et al. Review: use of electronic medical records for health outcomes research: a literature review. Med Care Res Rev. 66, 611–638 (2009).
6. Vito, D., Casagrande, G., Bianchi, C. & Costantino, M. L. How to extract clinically useful information from large amount of dialysis related stored data. Annual International Conference of the IEEE Engineering in Medicine & Biology Society. 2015, 6812–6815 (2015).
7. Alam, A. Computerization of hemodialysis records: a new era explored. Saudi Journal of Kidney Diseases & Transplantation. 21(3), 535–237 (2010).
8. Devic, B., Jelic, I. & Racki, S. Management of hemodialysis patients using simple informatics program. Acta Medica Croatica. 68(1), 43–48 (2014).
9. Wise, M. E. & Lovell, C. Public health surveillance in the dialysis setting: opportunities and challenges for using electronic health records. Seminars in Dialysis. 26(4), 399–406 (2013).
10. Pollak, V. E., Buncher, R. & Donovan, E. R. On-line computerized data handling system for treating patients with renal disease. Arch Intern Med. 137, 446–456 (1977).
11. Pollak, V. E. Computerization of the medical records: Utility in the care of patients with end-stage renal disease. Kidney Int. 24, 464–473 (1983).
12. Lorch, J. A., Pollak, V. E. Computerized Patient Record in Dialysis Practice. In: Replacement of Renal Function by Dialysis, 5th ed. England Kluwer Academic Publishers, London. pp. 2004, 539–553 (2004).
13. Chaudhry, B. et al. Systemic Review: Impact of health information technology on quality, efficiency, and costs of medical care. Ann Intern Med. 144, 742–752 (2006).
14. Pollak, V. E., Lorch, J. A. Effect of electronic patient record use on mortality in End Stage Renal Disease, a model chronic disease: retrospective analysis of 9 years of prospectively collected data. BMC Med Inf Decis Mak. 7, page number not for citation purposes (2007).
15. Sandhu, G. S. et al. Social Adaptability Index: application and outcomes in a dialysis population. Nephrol Dial Transplant. 26, 2667–2674 (2011).
16. Chua, H. R. et al. Predicting first-year mortality in incident dialysis patients with end-stage renal disease - the UREA5 study. Blood Purification. 37(2), 85–92 (2012).
17. Kim, C. H. et al. LDL cholesterol affects clinical outcomes in incident hemodialysis patients during the early stages of dialysis. Blood Purification. 38(2), 131–139 (2014).
18. Banerjee, T. et al. Vascular access type, inflammatory markers, and mortality in incident hemodialysis patients: the Choices for Healthy Outcomes in Caring for End-Stage Renal Disease (CHOICE) Study. American Journal of Kidney Diseases. 64(6), 954–961 (2014).
19. Chen, K. H. et al. Cardiothoracic ratio association with mortality in patients on maintenance peritoneal dialysis. Therapeutic Apheresis & Dialysis. 15(1), 81–11 (2011).
20. Dhingra, R. K., Young, E. W., Hulbert-Shearon, T. E., Leavey, S. F. & Port, F. K. Type of vascular access and mortality in US hemodialysis patients. Kidney Int. 60, 1443–1451 (2001).
21. Canaud, B. et al. DOPPS estimate of patient life years attributable to modifiable hemodialysis practices in France. Nephrol Ther. 4, 256–265 (2008).
22. Pison, R. L. et al. Facility Hemodialysis Vascular Access Use and Mortality in Countries Participating in DOPPS: An Instrumental Variable Analysis. Am J Kidney Dis. 33, 475–491 (2009).
23. Kimata, N. et al. Gender, low Kt/V, and mortality in Japanese hemodialysis patients: Opportunities for improvement through modifiable practices. Hemodial Int. 18, 596–606 (2014).
24. Nor Baizura, M. Y., Chan, Y. M., Zalilah Mohd, S. & Choo, B. H. Factors Associated with Quality of Life among Hemodialysis Patients in Malaysia. PLOS ONE. 8(12), e84152 (2013).
25. Hwang, S. J. et al. Impact of the clinical conditions at dialysis initiation on mortality in incident haemodialysis patients: a national cohort study in Taiwan. Nephrol Dial Transplant. 25, 2616–2624 (2010).
26. Chang, Y. K. et al. A Comparative Assessment of Survival Between Propensity Score-Matched Patients With Peritoneal Dialysis and Hemodialysis in Taiwan. Medicine. 91, 144–151 (2012).
27. Hayrinen, K., Saranto, K. & Nykanen, P. Definition, structure, content, use and impacts of electronic health records: A review of the research literature. Int J Med Inf. 77, 291–304 (2008).
28. Koppel, R. S., Zhu, X., Lew, N. L. & Lowrie, E. G. Body weight-for-height relationships predict mortality in maintenance hemodialysis patients. Kidney Int. 56, 1136–1148 (1999).
29. Leavey, S. F., Strawäderman, R. L., Jones, C. A., Port, F. K. & Held, P. J. Simple nutritional indicators as independent predictors of mortality in hemodialysis patients. Am J Kidney Dis. 31(6), 997–1006 (1998).
30. Lowrie, E. G., Laird, N. M., Parker, T. F. & Sargent, J. A. Effect of the Hemodialysis Prescription on Patient Morbidity — Report from the National Cooperative Dialysis Study. N Engl J Med. 305, 1176–1181 (1981).
31. The National Health Insurance Statistics. National Health Insurance Administration. Ministry of Health and Welfare, Taiwan. Available: http://www.mhi.gov.tw/English/webdata/webdata.aspx?menu=11&menu_id=296&amp;WD_ID=2966&webdata_id=4229 (2011).

Acknowledgements
This work was supported by grants from the Chang Gung Medical Research Fund (CMRPG5B0041; CMRPD390043). We deeply appreciate Yi-Chen Hsieh’s effort about the data collection and analysis in this study.

Author Contributions
Chang-Chyi Jenq wrote the main manuscript text. Cheng-Chieh Hung provide the main data. Kuo-Chang Juan prepared the figures. Kuang-Hung Hsu revised the text, and the did the main part of the data analysis. All authors discussed and reviewed the manuscript.
Additional Information

Competing Interests: The authors declare that they have no competing interests.

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2017